IN THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A process for the preparation of a controlled-release oral dosage form comprising:

(a) forming granules comprising oxycodone hydrochloride pharmaceutically active ingredient, alkyl cellulose and polymethacrylate, and

(b) drying said granules.

2. (original) The process of claim 1, further comprising adding aliphatic alcohol and regranulating and compressing said granules into tablets.

3. (original) The process of claim 1, wherein said granules are dried at 50°C.

4. (currently amended) A process for the preparation of a controlled-release oral dosage form comprising:

(a) forming spheroids comprising oxycodone hydrochloride pharmaceutically active ingredient, spheronizing agent, alkyl cellulose and polymethacrylate, and

(b) drying said granules.

5. (original) The process of claim 4, wherein the spheronizing agent is microcrystalline cellulose.

6. (original) The process of claim 4, further comprising film coating said spheroids.

7. (currently amended) A process for the preparation of a controlled-release oral dosage form comprising:

(a) wet granulating oxycodone hydrochloride pharmaceutically active ingredient, alkyl cellulose and polymethacrylate to form granules of said oxycodone hydrochloride,

(b) drying said granules,

(c) adding aliphatic alcohol, and

(d) regranulating and compressing said granules into tablets.

8. (new) The process of claim 1, wherein the tablets comprise 10mg oxycodone hydrochloride pharmaceutically active ingredient.

9. (new) The process of claim 8, wherein the dosage form provides at least a 12 hour therapeutic effect to a human patient in pain.

10. (new) The process of claim 2, wherein the tablets comprise 10mg oxycodone hydrochloride pharmaceutically active ingredient.

11. (new) The process of claim 10, wherein the dosage form provides at least a 12 hour therapeutic effect to a human patient in pain.

12. (new) The process of claim 1, wherein the tablets comprise 20mg oxycodone hydrochloride pharmaceutically active ingredient.

13. (new) The process of claim 12, wherein the dosage form provides at least a 12 hour therapeutic effect to a human patient in pain.

14. (new) The process of claim 2, wherein the tablets comprise 20mg oxycodone hydrochloride pharmaceutically active ingredient.

15. (new) The process of claim 14, wherein the dosage form provides at least a 12 hour therapeutic effect to a human patient in pain.